These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 2038782)

  • 1. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
    Kattan S; Collins JP; Mohr D
    Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
    Sarosdy MF; Hudnall CH; Erickson DR; Hardin TC; Novicki DE
    J Urol; 1989 Mar; 141(3):551-3. PubMed ID: 2645420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostaglandin E1 therapy for impotence, comparison with papaverine.
    Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
    J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
    Waldhauser M; Schramek P
    J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
    Moriel EZ; Rajfer J
    J Urol; 1993 May; 149(5 Pt 2):1299-300. PubMed ID: 8386779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients.
    Mahmoud KZ; el Dakhli MR; Fahmi IM; Abdel-Aziz AB
    J Urol; 1992 Mar; 147(3):623-6. PubMed ID: 1538443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.
    Zaher TF
    Int Urol Nephrol; 1998; 30(2):193-6. PubMed ID: 9607891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind randomized crossover study comparing intracorporeal prostaglandin E1 with combination of prostaglandin E1 and lidocaine in the treatment of organic impotence.
    Kattan S
    Urology; 1995 Jun; 45(6):1032-6. PubMed ID: 7771004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of multidose intracorporeal injection and audiovisual sexual stimulation in vasculogenic impotence.
    Katlowitz N; Albano GJ; Patsias G; Golimbu M; Morales P
    Urology; 1993 Dec; 42(6):695-7. PubMed ID: 8256402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
    Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
    Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracavernosal injection of pharmacological agents in the diagnosis and treatment of impotence.
    Siraj QH; Akhtar MA
    J Pak Med Assoc; 1989 Jul; 39(7):172-6. PubMed ID: 2504962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study with intracavernous injection of prostaglandin E1 versus papaverine for the diagnostic assessment of erectile impotence.
    Wang CJ; Wu CC; Huang CH; Chiang CP
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Nov; 8(11):585-90. PubMed ID: 1296038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of prostaglandin E1 for papaverine-failed erections.
    Reiss H
    Urology; 1989 Jan; 33(1):15-6. PubMed ID: 2911923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.